Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy Publisher Pubmed



Mohsenzadegan M1 ; Nowroozi MR2 ; Fotovvat A2 ; Bavandpour Baghshahi P3 ; Bokaie S4 ; Inanloo SH2 ; Sharifi L2
Authors

Source: Scandinavian Journal of Immunology Published:2022


Abstract

Despite the advances in the diagnosis and treatment of renal cell carcinoma (RCC), it remains one of the most deadly urological cancers. At present, using immune checkpoint inhibition and their combination with antiangiogenic therapy is the standard of care in patients with advanced RCC. Unfortunately, a considerable part of tumour-bearing hosts does not benefit from this type of treatment. However, our knowledge about the detailed role of mucin-domain containing-3 (TIM-3) in the RCC cells is little, and further studies are required in this field, but its significant expression in the RCC microenvironment makes this receptor a promising target for designing new monoclonal antibodies alone or in combination with other checkpoint inhibitors for RCC immunotherapy. © 2022 The Scandinavian Foundation for Immunology.
Related Docs
View other Related Docs
1. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
2. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
3. Clinical Potential of Pd-1/Pd-L1 Blockade Therapy for Renal Cell Carcinoma (Rcc): A Rapidly Evolving Strategy, Cancer Cell International (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Ali Akbar Amirzargar (2)
Other Related Docs
4. Targeted Knockdown of Tim3 by Short Hairpin Rnas Improves the Function of Anti-Mesothelin Car T Cells, Molecular Immunology (2021)
5. Sequential Monitoring of Tim-3 Mrna Expression in Blood and Urine Samples of Renal Transplant Recipients, Transplant Immunology (2019)
6. Tumor Immunology, Clinical Immunology (2022)
7. High Expression of Tim-3 and Kim-1 in Blood and Urine of Renal Allograft Rejection Patients, Transplant Immunology (2017)
8. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
9. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
10. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
11. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
12. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
13. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
14. Upregulation of Galectin-9 and Pd-L1 Immune Checkpoints Molecules in Patients With Chronic Lymphocytic Leukemia, Asian Pacific Journal of Cancer Prevention (2017)
15. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
16. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)
17. Crispri-Mediated Knock-Down of Prdm1/Blimp1 Programs Central Memory Differentiation in Ex Vivo-Expanded Human T Cells, BioImpacts (2022)
18. Evaluation of the Immune Checkpoint Factors in Idiopathic Membranous Nephropathy, Molecular and Cellular Probes (2023)
19. Tim-3 Genetic Variants and Risk of Behcet Disease in the Iranian Population, Anais Brasileiros de Dermatologia (2019)
20. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)